Persistent Asset Partners Ltd Makes New Investment in Nurix Therapeutics, Inc. $NRIX

Posted by Brenda Bartman on Aug 17th, 2026

Persistent Asset Partners Ltd acquired a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 30,973 shares of the company’s stock, valued at approximately $751,000.

Several other hedge funds also recently modified their holdings of NRIX. Global Retirement Partners LLC bought a new stake in Nurix Therapeutics during the second quarter worth about $82,000. Bank of New York Mellon Corp bought a new position in Nurix Therapeutics in the second quarter valued at approximately $6,614,000. State of Wyoming acquired a new position in shares of Nurix Therapeutics during the 2nd quarter worth approximately $112,000. Avalon Trust Co bought a new stake in shares of Nurix Therapeutics during the 2nd quarter worth approximately $64,000. Finally, Walleye Capital LLC bought a new stake in shares of Nurix Therapeutics during the 2nd quarter worth approximately $378,000.

Nurix Therapeutics Stock Performance

NRIX stock opened at $27.05 on Monday. The firm has a market capitalization of $2.81 billion, a PE ratio of -7.84 and a beta of 1.79. Nurix Therapeutics, Inc. has a 1-year low of $8.19 and a 1-year high of $27.35. The business’s 50 day simple moving average is $22.33 and its 200 day simple moving average is $18.32.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last posted its quarterly earnings results on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. The business had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. As a group, sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Analyst Ratings Changes

NRIX has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Friday, July 17th. Stifel Nicolaus upped their price target on shares of Nurix Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. BTIG Research reiterated a “buy” rating and issued a $32.00 price target on shares of Nurix Therapeutics in a research note on Friday, July 10th. Wells Fargo & Company lowered shares of Nurix Therapeutics from an “overweight” rating to a “hold” rating and lowered their price objective for the stock from $28.00 to $25.00 in a research note on Monday, June 8th. Finally, Truist Financial upped their target price on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, July 10th. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $34.21.

Get Our Latest Stock Report on NRIX

Insider Activity

In other news, insider Gwenn Hansen sold 5,394 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.00, for a total value of $107,880.00. Following the transaction, the insider directly owned 115,005 shares of the company’s stock, valued at $2,300,100. This represents a 4.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 4,761 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $24.36, for a total transaction of $115,977.96. Following the sale, the chief financial officer owned 40,166 shares of the company’s stock, valued at approximately $978,443.76. This represents a 10.60% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,314 shares of company stock worth $589,361 over the last three months. Insiders own 6.70% of the company’s stock.

Nurix Therapeutics Company Profile

(Free Report)

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.

Institutional Ownership by Quarter for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.